Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alnylam’s Amvuttra To Take Off From Onpattro’s Runway

Most Onpattro Patients Expected To Switch

Executive Summary

The company won approval in hATTR amyloidosis polyneuropathy for the RNAi drug, which offers quarterly subcutaneous dosing versus Onpattro’s I.V. administration every three weeks.

You may also be interested in...



Alnylam Stays Mum On APOLLO-B Amid Anticipation Over Major Readout

The company announced a respectable increase in second quarter sales and expects to announce topline results within the next three weeks for the Phase III trial of Onpattro in ATTR-CM.

Keeping Track: US FDA Okays Alnylam’s siRNA Amvuttra, Alopecia Claim For Lilly’s Olumiant; Sierra Submits Momelotinib

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

AstraZeneca Closes Amyloidosis Gap On Alnylam After Eplontersen Win

AstraZeneca is preparing a US filing for hereditary transthyretin-mediated amyloid polyneuropathy for eplontersen, which it hopes will compete with Pfizer and Alnylam's therapies in that rare disease space.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146551

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel